IPO - Lumos Diagnostics Holdings Limited - 5 July 2021 #, page-4

2 July'21 - Positive article about LDX listing + short revenue summary

_{https://www.thesentiment.com.au/ipo-watch-lumos-to-accelerate-decentralised-healthcare-diagnostics-with-187m-float/}

SG Hiscock & Company (SGH) has launched a medical technology fund, investing in Australian medical technology companies
_{https://www.money*management.com.au/news/funds-management/sg-hiscock-launches-medical-technology-fund} (remove * in link)
"The fund would be run by the SGH emerging companies team and guided by the SGH medical technology advisory board:
- Brenda Shanahan as chair (non-executive director, SGH; non-executive director, Clinuvel Pharmaceuticals; former chair, St Vincent’s Medical Research Institute; chair, Aitkenhead Centre for Medical Discovery);
- Professor Mark Cook (chair of medicine, St Vincent’s Hospital; chair of medicine, University of Melbourne; state chair, Victoria, Australian and New Zealand Association of Neurologists; director, Graeme Clarke Institute for Biomedical Engineering);
- Sam Lanyon (co-CEO and co-founder, Planet Innovation; executive chair, Lumos Diagnostics);
- Stephen Hiscock (chair and managing director, SGH; director, DMP Asset Management)
- Hamish Tadgell (head of research, SGH; portfolio manager, SGH20).

SGH would also establish a registered charitable foundation which will be funded by 10% of net revenue from the SGH Medical Technology fund, including performance fees."

And naturally, above new SG Hiscock medical tech fund has invested in the LDX IPO -

30 June'21 - SG Hiscock hunting $100m for new healthcare fund

_{https://www.a*fr.com/street-talk/sg-hiscock-hunting-100m-for-new-healthcare-fund-20210630-p585nj} (remove the * in link to access)